Radiation therapy developer Accuray has applied to the Chinese National Medical Products Administration for market clearance for its Tomo C radiation therapy system.
The application was filed under the auspices of the CNNC-Accuray joint venture, which was established in 2019 and is based in Tianjin, China, the company said.
Tomo C offers integrated helical fan-beam imaging and radiation delivery in conventionally fractionated or ultrahypofractionated treatments, according to the firm.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
